Experienced in Episodic Ataxia with Nystagmus

Dr. Jeffrey M. Statland

Neurology
The University of Kansas Hospital
Kansas University Physicians Inc
4000 Cambridge St, Suite G600, 
Kansas City, KS 
Clinical Trials:Currently Recruiting for 3 Trials
Accepting New Patients
Offers Telehealth
Experienced in Episodic Ataxia with Nystagmus
The University of Kansas Hospital
Kansas University Physicians Inc
4000 Cambridge St, Suite G600, 
Kansas City, KS 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Jeffrey Statland is a Neurologist in Kansas City, Kansas. Dr. Statland and is rated as an Experienced provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Facioscapulohumeral Muscular Dystrophy (FSHD), Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Paramyotonia Congenita, and Gastrostomy. Dr. Statland is currently accepting new patients.

His clinical research consists of co-authoring 110 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Internal Medicine in KS
Hospital Affiliations
University Of Kansas Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

KANSAS UNIVERSITY PHYSICIANS INC
4000 Cambridge St, Suite G600, Kansas City, KS 66160
Other Locations
KANSAS UNIVERSITY PHYSICIANS INC
3901 Rainbow Blvd, Kansas City, KS 66160
KANSAS UNIVERSITY PHYSICIANS INC
3599 Rainbow Blvd, Kansas City, KS 66103

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Establishing Biomarkers and Clinical Endpoints in Myotonic Dystrophy Type 1 (END-DM1)
Enrollment Status: Recruiting
Publish Date: June 06, 2025
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis
Enrollment Status: Recruiting
Publish Date: May 08, 2025
Intervention Type: Drug
Study Drug: MN-166
Study Phase: Phase 2/Phase 3
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Enrollment Status: Recruiting
Publish Date: April 23, 2025
Intervention Type: Diagnostic test, Device
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
Enrollment Status: Enrolling_by_invitation
Publish Date: June 04, 2025
TRIAL READY (Clinical Trial Readiness)
TRIAL READY (Clinical Trial Readiness)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Pitolisant on Excessive Daytime Sleepiness and Other Non-Muscular Symptoms in Patients With Myotonic Dystrophy Type 1, Followed by an Open-Label Extension
Enrollment Status: Completed
Publish Date: April 25, 2025
Intervention Type: Drug
Study Drug: Pitolisant
Study Phase: Phase 2
GRASP-LGMD: Defining Clinical Endpoints in LGMD
GRASP-LGMD: Defining Clinical Endpoints in LGMD
Enrollment Status: Active_not_recruiting
Publish Date: March 10, 2025
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
A Phase 2, Two-Part, Multiple-Ascending-Dose Study of SRP-5051 for Dose Determination, Then Dose Expansion, in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment
Enrollment Status: Terminated
Publish Date: March 10, 2025
Intervention Type: Drug
Study Drug: SRP-5051 Exon 51-Skipping Treatment
Study Phase: Phase 2
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051
Enrollment Status: Terminated
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: SRP-5051
Study Phase: Phase 1/Phase 2
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind, Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Ambulatory Subjects With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: August 26, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
A Multi-center, Randomized, Double-blind, Placebo Controlled Phase III Study to Assess the Efficacy, Safety, and Tolerability of PXT3003 in Charcot-Marie-Tooth Type 1A (CMT1A)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2024
Intervention Type: Drug
Study Drug: (RS)-Baclofen, Naltrexone Hydrochloride and D-Sorbitol
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
A Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy and Safety Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy and Open-Label Extension
Enrollment Status: Completed
Publish Date: January 18, 2024
Intervention Type: Drug
Study Drug: Ataluren
Study Phase: Phase 3
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Expanded Access Protocol (EAP) of Idebenone in Patients With Duchenne Muscular Dystrophy
Enrollment Status: No_longer_available
Publish Date: April 21, 2023
Intervention Type: Drug
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease Types 1 and X
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
A Multicenter Open-Label Study on the Safety and Efficacy of Deflazacort (Emflaza) in Subjects With Limb-Girdle Muscular Dystrophy 2I (LGMD2I)
Enrollment Status: Terminated
Publish Date: June 27, 2022
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
A Randomized, Double-Blind, Placebo-Controlled, Global Phase 3 Study of Edasalonexent in Pediatric Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: June 21, 2022
Intervention Type: Drug
Study Phase: Phase 3
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Phase 2 Clinical Pharmacology Study to Assess Dystrophin Levels in Subjects With nmDMD Before and After Treatment With Ataluren
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
A Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of WVE-210201 With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy (DYSTANCE 51)
Enrollment Status: Terminated
Publish Date: May 20, 2021
Intervention Type: Drug
Study Phase: Phase 2/Phase 3
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
A Multicenter, Double-blind, Placebo-controlled, Phase 1 Study of WVE-210201 Administered Intravenously to Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: April 08, 2019
Intervention Type: Drug
Study Phase: Phase 1
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
A Phase 3 Switchover Study of the Efficacy and Safety of BMN 701 (GILT-tagged Recombinant Human GAA) and Long-Term Study for Extended Treatment in rhGAA Exposed Subjects With Late-onset Pompe Disease
Enrollment Status: Terminated
Publish Date: June 14, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 20 Less Clinical Trials

110 Total Publications

Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study.
Clinical Trial Readiness in Limb Girdle Muscular Dystrophy R1 (LGMDR1): A GRASP Consortium Study.
Journal: Annals of clinical and translational neurology
Published: January 08, 2025
Similar Doctors
Distinguished in Episodic Ataxia with Nystagmus
Dr. Richard M. Dubinsky
Neurology
Distinguished in Episodic Ataxia with Nystagmus
Dr. Richard M. Dubinsky
Neurology

Kansas University Physicians Inc

4000 Cambridge St, Suite G600, 
Kansas City, KS 
 (0.1 mi)
913-588-1227
Experience:
43+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Richard Dubinsky is a Neurologist in Kansas City, Kansas. Dr. Dubinsky has been practicing medicine for over 43 years and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Huntington Disease, Drug Induced Dyskinesia, Tourette Syndrome, and Tardive Dyskinesia. Dr. Dubinsky is currently accepting new patients.

Advanced in Episodic Ataxia with Nystagmus
Dr. Omar H. Jawdat
Neurology | Nephrology
Advanced in Episodic Ataxia with Nystagmus
Dr. Omar H. Jawdat
Neurology | Nephrology

Kansas University Physicians Inc

3901 Rainbow Blvd, 
Kansas City, KS 
 (0.2 mi)
913-588-3315
Languages Spoken:
English, Arabic
See accepted insurances
Accepting New Patients
Offers Telehealth

Omar Jawdat is a Neurologist and a Nephrologist in Kansas City, Kansas. Dr. Jawdat and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's Disease), Primary Lateral Sclerosis, Inclusion Body Myositis, Spinal Muscular Atrophy (SMA), and Gastrostomy. Dr. Jawdat is currently accepting new patients.

Advanced in Episodic Ataxia with Nystagmus
Dr. Tekalign A. Burka
Neurology
Advanced in Episodic Ataxia with Nystagmus
Dr. Tekalign A. Burka
Neurology

Kansas University Physicians Inc

4000 Cambridge St, 
Kansas City, KS 
 (0.1 mi)
913-588-1227
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tekalign Burka is a Neurologist in Kansas City, Kansas. Dr. Burka and is rated as a Distinguished provider by MediFind in the treatment of Episodic Ataxia with Nystagmus. His top areas of expertise are Migraine, Migraine with Brainstem Aura, Hereditary Sensory and Autonomic Neuropathy Type 2, and Congenital Insensitivity to Pain with Anhidrosis. Dr. Burka is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Statland's expertise for a condition
ConditionClose
View All 8 Elite Conditions
View All 24 Distinguished Conditions
View All 15 Advanced Conditions
View All 54 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile